Pacira BioSciences (PCRX) EBITDA Margin (2010 - 2026)

Pacira BioSciences' EBITDA Margin history runs 17 years deep, the most recent figure standing at 3.89% for Q1 2026.

• On a quarterly basis, EBITDA Margin rose 271.0% year-over-year to 3.89% in Q1 2026; TTM through Mar 2026 was 3.28%, a 1532.0% increase from a year earlier, with the FY2025 full-year figure at 2.64%, up 1311.0% from the prior year.
• EBITDA Margin climbed to 3.89% in Q1 2026 per PCRX's latest filing, from 1.19% in the prior quarter.
• Across five years, EBITDA Margin topped out at 23.53% in Q2 2023 and bottomed at 82.77% in Q3 2024.
• The 5-year median for EBITDA Margin is 7.91% (2024), against an average of 3.74%.
• Across the five-year window, EBITDA Margin tumbled 9358 bps in 2024 and jumped 8631 bps in 2025, its largest moves.
• Year by year, EBITDA Margin stood at 2.01% in 2022, then surged by 810 bps to 18.3% in 2023, then slipped by 28 bps to 13.19% in 2024, then slumped by 91 bps to 1.19% in 2025, then soared by 227 bps to 3.89% in 2026.
• Per Business Quant, the three latest PCRX EBITDA Margin figures stand at 3.89% (Q1 2026), 1.19% (Q4 2025), and 3.54% (Q3 2025).